Promotional tone in reviews of menopausal hormone therapy after the women's health initiative: An analysis of published articles

PLoS Medicine

Volumn 8, Issue 3, 2011, Pages

  Fugh Berman, Adriane ^a   McDonald, Christina Pike ^a   Bell, Alicia M ^a   Bethards, Emily Catherine ^a   Scialli, Anthony R ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ACCURACY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FEMALE; HEALTH PROMOTION; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; MENOPAUSE; METHODOLOGY; OBSERVATIONAL STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; ADULT; ARTICLE; BREAST TUMOR; CONFLICT OF INTEREST; ESTROGEN THERAPY; HEALTH PERSONNEL ATTITUDE; LITERATURE; PHYSICIAN; PSYCHOLOGICAL ASPECT; UNITED STATES; WOMEN'S HEALTH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PHYSICIANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; UNITED STATES; WOMEN'S HEALTH;

EID: 79953729071     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000425     Document Type: Review

References (55)

1. Power ML, Schulkin J, Rossouw JE, (2007) Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. Menopause 14: 20-28.
2. Power ML, Baron J, Schulkin J, (2008) Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy. Med Decis Making 28: 411-418.
3. Power ML, Anderson BL, Schulkin J, (2009) Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 16: 500-508.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
5. The Women's Health Initiative Steering C (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
6. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291: 2947-58.
7. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, et al. (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293: 935-48.
8. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, et al. (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348: 1839-1854.
9. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, et al. (2005) Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: Results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 165: 1976-1986.
10. Majumdar SR, Almasi EA, Stafford RS, (2004) Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 292: 1983-1988.
11. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, et al. (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670-1674.
12. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, et al. (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360: 573-587.
13. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, et al. (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684-1692.
14. Stafford RS, Saglam D, Causino N, Blumenthal D, (1997) Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol 177: 381-387.
15. Saver BG, Taylor TR, Woods NF, Stevens NG, (1997) Physician policies on the use of preventive hormone therapy. Am J Prev Med 13: 358-365.
16. Brett AS, Carney PI, McKeown RE, (2005) Brief report: Attitudes toward hormone therapy after the Women's Health Initiative: a comparison of internists and gynecologists. J Gen Intern Med 20: 416-418.
17. Spangler L, Reed SD, Nekhyludov L, Grothaus LC, LaCroix AZ, et al. (2009) Provider attributes associated with hormone therapy prescribing frequency. Menopause 16: 810-816.
18. Hersh AL, Stefanick ML, Stafford RS, (2004) National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291: 47-53.
19. Fugh-Berman A, Scialli AR, (2006) Gynecologists and estrogen: An affair of the heart. Perspect Biol Med 49: 115-130.
20. Singer N, (2009) August 4 Medical papers by ghostwriters pushed therapy. The New York Times Available: http://www.nytimes.com/2009/08/05/health/research/05ghost.html. Accessed 4 Aug 2009.
21. Ross JS, Hill KP, Egilman DS, Krumholz HM, (2008) Guest authorship and ghostwriting in publications related to rofecoxib. JAMA 299: 1800-1812.
22. Steinman MA, Bero LA, Chren M, Landefeld CS, (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: 284-293.
23. Healy D, Cattel D, (2003) Interface between authorship, industry, and science in the domain of therapeutics. Brit J Psych 183: 22-27.
24. Fugh-Berman A, Melnick D, (2008) Off-label promotion, on-target sales. PLoS Med 5: e210 doi:10.1371/journal.pmed.0050210.
25. Fauber J, Rust S, (2009) January 25 UW course for doctors pushed risky therapy. Milwaukee Journal Sentinel Available: http://www.jsonline.com/features/health/38283649.html. Accessed 5 February 2011.
26. Fauber J, Kissinger M, (2009) August 15 UW linked to ghostwriting. Milwaukee Journal Sentinel Available: http://www.jsonline.com/features/health/53315032.html. Accessed 5 February 2011.
27. Publication Program Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 20 November 2010.
28. Publication Program A Proposal for Wyeth-Ayerst Pharmaceuticals- Council on Hormone Education, Scientific Update on Hormones and Postmenopausal Health. Available: http://dida.library.ucsf.edu/tid/iyb37b10. Accessed 20 November 2010.
29. Randolph JJ, (2008) Online kappa calculator. Available: http://justus.randolph.name/kappa. Accessed 26 August 2009.
30. Lexchin J, Bero LA, Djulbegovic B, Clark O, (2003) Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326: 1167-1170.
31. Jørgensen AW, Hilden J, Gøtzsche PC, (2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ 333: 782.
32. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC, (2008) Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMC Med Res Methodol 8: 60.
33. Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J, (2009) Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychother Psychosom 78: 228-232.
34. Rose J, (2008) Industry influence in the creation of pay-for-performance quality measures. Qual Manag Health Care 17: 27-34.
35. Hemminki E, (2003) Opposition to unpopular research results: Finnish professional reactions to the WHI findings. Health Policy 69: 283-291.
36. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, et al. (2008) Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167: 1207-1216.
37. American College of Cardiology ACCEL: ACCF's Disclosure/conflict of interest policy. Available: http://stage.acc.org/accel_disclosures.htm. Accessed November 26, 2010.
38. Bush TM, Bonomi AE, Nekhlyudov L, Ludman EJ, Reed SD, et al. (2007) How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J Gen Intern Med 22: 1311-1316.
39. Stelfox HT, Chua G, O'Rourke K, Detsky AS, (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338: 101-106.
40. Tatsioni A, Siontis GCM, Ioannidis JPA, (2010) Partisan perspectives in the medical literature: A study of high frequency editorialists favoring hormone replacement therapy. J Gen Int Med 25: 914-919.
41. Matheson A, (2008) Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 3: 355-382.
42. Glinert LH, (2005) TV commercials for prescription drugs: a discourse analytic perspective. Res Social Admin Pharm 1: 158-184.
43. [No authors listed] (2009) Self-plagiarism: Unintentional, harmless, or fraud? Lancet 374: 664.
44. PLoS Medicine (2009) Ghostwriting: The dirty little secret of medical publishing that just got bigger. Available: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000156. Accessed 12 February 2011.
45. Fugh-Berman AJ, (2010) The haunting of medical journals: How ghostwriting sold "HRT". PLoS Med 7: e1000335 doi:10.1371/journal.pmed.1000335.
46. Draft of Low-Dose Review Paper [With Annotations] DWRITE073011. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/qlc37b10. Accessed 26 November 2010.
47. Low-dose Review Paper Submitted to Climacteric DWRITE73106. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/qnb37b10. Accessed 26 November 2010.
48. Response Letter to Alastair MacLennan Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). DWRITE072945. Available: http://dida.library.ucsf.edu/tid/qib37b10. Accessed 26 November 2010.
49. Draft of metabolic paperDELCA032-028548 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/czb37b10. Accessed 26 November 2010.
50. Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Plasma Lipids and Lipoproteins, Coagulation Factors, and Carbohydrate Metabolism Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). DELCA032-028549. Available: http://dida.library.ucsf.edu/tid/czc37b10. Accessed 26 November 2010.
51. Inconsistency in Epidemiological Findings on Postmenopausal Hormone Therapy and Breast Cancer DWRITE078512. (Exh. 96 to Janas Depos.) Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/rrb37b10. Accessed 26 November 2010.
52. Re: Draft of Manuscript DWRITE078370. (Exh. 95 to Janas Depos.) Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/rqc37b10. Accessed 26 November 2010.
53. Janas Deposition: 483:11-485:13 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/pdf/skc37b10. Accessed 26 November 2010.
54. Endometrial paper and action steps from last meeting DELCA031-019050 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/search?query=DELCA031-019050&ct=1. Accessed 26 November 2010.
55. Endometrial Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate DELCA031-019052. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/pdf/cvc37b10. Accessed 26 November 2010.